Evaluating the Utility of Initial Examinations in Retinopathy of Prematurity

IF 9.5 1区 医学 Q1 OPHTHALMOLOGY Ophthalmology Pub Date : 2025-06-01 Epub Date: 2025-01-08 DOI:10.1016/j.ophtha.2025.01.004
Francisco Altamirano MD , Melissa Yuan MD , Sandra Hoyek MD , Daniel Hu BA , Muhammad Abidi BS , Celine Chaaya MD , Hanna De Bruyn BS , Anne Fulton MD , Iason S. Mantagos MD, PhD , Carolyn Wu MD , Ryan Gise MD , Efren Gonzalez MD , Deborah K. VanderVeen MD , Nimesh A. Patel MD
{"title":"Evaluating the Utility of Initial Examinations in Retinopathy of Prematurity","authors":"Francisco Altamirano MD ,&nbsp;Melissa Yuan MD ,&nbsp;Sandra Hoyek MD ,&nbsp;Daniel Hu BA ,&nbsp;Muhammad Abidi BS ,&nbsp;Celine Chaaya MD ,&nbsp;Hanna De Bruyn BS ,&nbsp;Anne Fulton MD ,&nbsp;Iason S. Mantagos MD, PhD ,&nbsp;Carolyn Wu MD ,&nbsp;Ryan Gise MD ,&nbsp;Efren Gonzalez MD ,&nbsp;Deborah K. VanderVeen MD ,&nbsp;Nimesh A. Patel MD","doi":"10.1016/j.ophtha.2025.01.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To assess the utility of the first or second examinations for retinopathy of prematurity (ROP) in a medium-risk cohort of infants and to propose an optimization to the current ROP screening guidelines.</div></div><div><h3>Design</h3><div>Retrospective consecutive study.</div></div><div><h3>Participants</h3><div>Infants screened for ROP between January 2017 and August 2023 at 3 different tertiary-level care neonatal intensive care units.</div></div><div><h3>Methods</h3><div>Analysis of patients who did not meet criteria for microprematurity or nanoprematurity (those born at ≥ 27 weeks and weighing ≥ 800 g).</div></div><div><h3>Main Outcome Measures</h3><div>The primary outcomes included the rates of ROP and treatment-warranted ROP (TW-ROP), the presence of TW-ROP at the first or second inpatient examinations, the number of inpatient examinations performed before the first ROP diagnosis, and the overall number of inpatient examinations performed.</div></div><div><h3>Results</h3><div>A total of 2004 neonates were screened for ROP, among whom 1125 (56.1%) met the inclusion criteria. Of those, 237 neonates (21.1%) had ROP. Eleven infants (1.0%) required treatment for active disease. The median postmenstrual age (PMA) at first ROP diagnosis was 35.3 weeks (interquartile range [IQR], 33.7–37 weeks; range, 30.3–46.7 weeks). The median PMA at stage 3 diagnosis was 39.3 weeks (IQR, 38.3–41.2 weeks; range, 35.1–44.4 weeks). The median PMA at first treatment was 39.6 weeks (IQR, 35.8–43.3 weeks; range, 35.3–49.6 weeks). The median number of inpatient examinations was 2.0 (IQR, 1–4 examinations) for traditional screening, 1.0 examination (IQR, 1–3 examinations) after eliminating the first ROP inpatient examination, and 1.0 examination (IQR, 1–2 examinations) after eliminating the first and second ROP examinations (<em>P</em> &lt; 0.001). No patients met type 1 ROP treatment criteria at either the first or second inpatient examination (100% sensitivity for TW-ROP). In this cohort, starting examinations at 34 weeks’ PMA could save 30.6% of inpatient examinations.</div></div><div><h3>Conclusions</h3><div>In infants not meeting criteria for microprematurity or nanoprematurity, no type 1 ROP was diagnosed at either of the first 2 inpatient examinations. We propose an amendment algorithm (FIRST-ROP) in which ROP examinations start at 34 weeks’ PMA for neonates born at ≥27 weeks gestational age and ≥800 grams.</div></div><div><h3>Financial Disclosure(s)</h3><div>The author(s) have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19533,"journal":{"name":"Ophthalmology","volume":"132 6","pages":"Pages 713-717"},"PeriodicalIF":9.5000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0161642025000053","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose

To assess the utility of the first or second examinations for retinopathy of prematurity (ROP) in a medium-risk cohort of infants and to propose an optimization to the current ROP screening guidelines.

Design

Retrospective consecutive study.

Participants

Infants screened for ROP between January 2017 and August 2023 at 3 different tertiary-level care neonatal intensive care units.

Methods

Analysis of patients who did not meet criteria for microprematurity or nanoprematurity (those born at ≥ 27 weeks and weighing ≥ 800 g).

Main Outcome Measures

The primary outcomes included the rates of ROP and treatment-warranted ROP (TW-ROP), the presence of TW-ROP at the first or second inpatient examinations, the number of inpatient examinations performed before the first ROP diagnosis, and the overall number of inpatient examinations performed.

Results

A total of 2004 neonates were screened for ROP, among whom 1125 (56.1%) met the inclusion criteria. Of those, 237 neonates (21.1%) had ROP. Eleven infants (1.0%) required treatment for active disease. The median postmenstrual age (PMA) at first ROP diagnosis was 35.3 weeks (interquartile range [IQR], 33.7–37 weeks; range, 30.3–46.7 weeks). The median PMA at stage 3 diagnosis was 39.3 weeks (IQR, 38.3–41.2 weeks; range, 35.1–44.4 weeks). The median PMA at first treatment was 39.6 weeks (IQR, 35.8–43.3 weeks; range, 35.3–49.6 weeks). The median number of inpatient examinations was 2.0 (IQR, 1–4 examinations) for traditional screening, 1.0 examination (IQR, 1–3 examinations) after eliminating the first ROP inpatient examination, and 1.0 examination (IQR, 1–2 examinations) after eliminating the first and second ROP examinations (P < 0.001). No patients met type 1 ROP treatment criteria at either the first or second inpatient examination (100% sensitivity for TW-ROP). In this cohort, starting examinations at 34 weeks’ PMA could save 30.6% of inpatient examinations.

Conclusions

In infants not meeting criteria for microprematurity or nanoprematurity, no type 1 ROP was diagnosed at either of the first 2 inpatient examinations. We propose an amendment algorithm (FIRST-ROP) in which ROP examinations start at 34 weeks’ PMA for neonates born at ≥27 weeks gestational age and ≥800 grams.

Financial Disclosure(s)

The author(s) have no proprietary or commercial interest in any materials discussed in this article.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估早产儿视网膜病变初始检查的效用:中等风险队列中FIRST-ROP算法的建议。
目的:评估中等风险婴儿早产儿视网膜病变(ROP)的第一次或第二次检查的效用,并对当前ROP筛查指南提出优化建议。设计:回顾性连续研究。研究对象:2017年1月至2023年8月在三个不同的三级新生儿重症监护病房筛查的ROP婴儿。方法:分析不符合微或纳米再成熟标准的患者(出生≥27周,体重≥800克)。主要结局指标:主要结局包括ROP和治疗保证ROP (TW-ROP)的发生率,第一次或第二次住院检查时TW-ROP的存在,第一次ROP诊断前进行的住院检查次数,以及进行的住院检查总次数。结果:共筛查新生儿ROP 2004例,其中1125例(56.1%)符合纳入标准。其中237例(21.1%)发生ROP。11名婴儿(1.0%)因活动性疾病需要治疗。首次诊断ROP时经后年龄(PMA)中位数为35.3周(IQR, 33.7-37周;范围:30.3-46.7周)。3期诊断时的中位PMA为39.3周(IQR, 38.3-41.2周;范围:35.1-44.4周)。首次治疗时的中位PMA为39.6周(IQR, 35.8-43.3周;范围:35.3-49.6周)。传统筛查的住院检查中位数为2.0 (IQR, 1-4次检查),取消第一次ROP住院检查后为1.0 (IQR, 1-3),取消第一次和第二次ROP检查后为1.0 (IQR, 1-2)。结论:在不符合显微和/或纳米再生标准的婴儿中,前两次住院检查均未出现1型ROP。我们提出了一种修正算法(FIRST-ROP),其中对于≥27周孕周且≥800克的新生儿,ROP检查从PMA 34周开始。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Ophthalmology
Ophthalmology 医学-眼科学
CiteScore
22.30
自引率
3.60%
发文量
412
审稿时长
18 days
期刊介绍: The journal Ophthalmology, from the American Academy of Ophthalmology, contributes to society by publishing research in clinical and basic science related to vision.It upholds excellence through unbiased peer-review, fostering innovation, promoting discovery, and encouraging lifelong learning.
期刊最新文献
Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease Intravascular Papillary Endothelial Hyperplasia (Masson’s Tumor) of the Eyelid Intravitreal Aflibercept 8 mg for Diabetic Macular Edema Which of These Fundus Images Was Created by Artificial Intelligence? Dead Bag-Associated Uveitis-Glaucoma-Hyphema Syndrome
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1